Vice President, Market Access & Strategy, Commercial

Position: Vice President Market Access & Strategy Commercial

Philadelphia PA (Hybrid)

Cabaletta Bio (Nasdaq: CABA) is a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies designed specifically for patients with autoimmune diseases. The CABA platform encompasses two complementary strategies which aim to advance the discovery and development of engineered T cell therapies with the potential to become deep and durable perhaps curative treatments for a broad range of autoimmune diseases. The lead CARTA (Chimeric Antigen Receptor T cells for Autoimmunity) strategy is prioritizing the development of rese-cel a 4-1BB-containing fully human CD19-CAR T cell investigational therapy. Rese-cel is currently being evaluated in the RESET (REstoring SElf-Tolerance) clinical development program spanning multiple therapeutic areas including rheumatology neurology and dermatology. The company recently presented final phase 1/2 data for rese-cel in myositis and expects to initiate the pivotal myositis trial this year. Cabaletta Bios headquarters and labs are based in Philadelphia PA. For more information please visit and connect with us on LinkedIn.

At Cabaletta we are driven by the shared mission of developing cures where a patients own cells are used to fight disease. We are building a culture grounded in the knowledge that successful cures can be achieved for patients if every member of the Cabaletta is focused on the success of the team. To nurture this we make an active commitment to the well-being and continuous growth of each employee who joins the this way we are not only working to improve the lives of patients but of everyone involved. And were proud that for 3 years in a row weve been nationally recognized by Great Place to Work and Fortune as one of the Top 10 Best Small/Medium Workplaces in Biopharma!

About the Position

Reporting to the Chief Commercial Officer the Vice President (VP) Market Access & Strategy is responsible for establishing the strategic foundation for pricing reimbursement policy and evidence generation to support successful commercialization of Cabaletta Bios CAR-T therapies. This role ensures optimal access through strong value demonstration reimbursement infrastructure and proactive policy strategy.

Key Responsibilities

Pricing Strategy

• Lead development of U.S. pricing strategy aligned with product value market dynamics and access goals.

Medicare & Medicaid Strategy

• Lead Medicare billing coding development and submission processes.
• Oversee Medicaid strategy and execution across states.

Provider Reimbursement

• Develop and implement provider reimbursement strategies including coding and payment pathways.

HEOR & Value Evidence

• Lead Health Economics and Outcomes Research (HEOR) strategy.
• Partner with Medical Affairs to generate evidence supporting payer value propositions.

Market Research & Insights

• Oversee payer and hospital market research to inform pricing access strategy and evidence needs.

Government Affairs & Policy

• Monitor and shape healthcare policy impacting reimbursement and access.
• Engage with external stakeholders and industry groups.

Payer Tools & Communications

• Lead development of payer-focused materials and promotional tools to communicate value effectively.

Advisory Boards & Stakeholder Alignment

• Co-lead payer and hospital advisory boards to refine strategy and gather insights.

Pipeline & Business Development Support

• Partner with New Product Planning (NPP) on future indications and business development opportunities.

Qualifications

• Advanced degree preferred (MBA PhD PharmD MD or equivalent).
• 15 years of experience in pricing reimbursement market access strategy or HEOR.
• Deep expertise in Medicare/Medicaid policy coding and reimbursement frameworks.
• Experience in cell/gene therapy or complex specialty products strongly preferred.
• Strong analytical strategic and cross-functional leadership skills.

Our name Cabaletta is derived from the operatic term that represents a rapid repetitive and technically challenging section of an operatic aria where the second act is designed to showcase the skills of the lead singer. Analogously Cabaletta Bio strives to achieve rapid and repetitive product development building on our indication prioritization and biologic platform that targets the driver of specific autoimmune diseases without the need for long-term immunosuppression.

For more information please visit most important asset is our people and we offer competitive benefits PTO and stock option plans.

Cabaletta Bio is an equal opportunity employer. We do not discriminate on the basis of race color gender gender identity sexual orientation age religion national or ethnic origin disability protected veteran status or any other basis protected by applicable law.

#LI-HYBRID